Locally Advanced Breast Cancer (LABC) (DBCOND0034432)

Identifiers

Synonyms

Locally Advance Breast Cancer (LABC) / Locally Advanced Breast Cancer / Locally advanced breast cancer (disorder) / Malignant neoplasm of breast of unspecified site / Malignant neoplasm of breast / Malignant breast neoplasm / Breast cancer / Malignant neoplasm of breast (disorder) / Breast tumor malignant / Breast tumour malignant / Breast cancer NOS / Breast cancer stage unspecified

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Anastrozole	A competitive, selective, non-steroidal aromatase inhibitor used as adjuvant therapy for the treatment of hormone receptor-positive breast cancer in postmenopausal women.	Aromatasetarget ATP-dependent translocase ABCB1transporter Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 2C8enzyme UDP-glucuronosyltransferase 1A4enzyme UDP-glucuronosyltransferase 1A3enzyme UDP-glucuronosyltransferase 2B7enzyme Cytochrome P450 1A2enzyme Cytochrome P450 2C9enzyme
Docetaxel	A taxoid antineoplastic agent used in the treatment of various cancers, such as locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, and head and neck cancer.	Apoptosis regulator Bcl-2target Tubulin beta-1 chaintarget Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 10transporter Cytochrome P450 1B1enzyme Microtubule-associated protein 2target Microtubule-associated protein 4target Microtubule-associated protein tautarget Solute carrier organic anion transporter family member 1B3transporter Solute carrier family 22 member 7transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-binding cassette sub-family C member 2transporter Multidrug resistance-associated protein 1transporter Nuclear receptor subfamily 1 group I member 2target
Elacestrant	An estrogen receptor antagonist used to treat ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.	Estrogen receptortarget Cytochrome P450 3A4enzyme Cytochrome P450 2A6enzyme Cytochrome P450 2C9enzyme Solute carrier organic anion transporter family member 2B1transporter ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter
Hyaluronidase (human recombinant)	An enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.	Hyaluronic acidtarget Transforming growth factor beta-1 proproteintarget
Ixabepilone	A microtubule inhibitor administered in combination with capecitabine or alone in the treatment of metastatic or locally advanced breast cancer that has shown inadequate response to taxanes and anthracyclines.	Tubulin beta-3 chaintarget Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter
Olaparib	A poly (ADP-ribose) polymerase (PARP) inhibitor used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.	Poly [ADP-ribose] polymerase 1target Cytochrome P450 3A4enzyme Cytochrome P450 2B6enzyme Poly [ADP-ribose] polymerase 2target Protein mono-ADP-ribosyltransferase PARP3target Cytochrome P450 3A5enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Aldo-keto reductase family 1 member C3target UDP-glucuronosyltransferase 1A1enzyme Albumincarrier Alpha-1-acid glycoprotein 1carrier
Pertuzumab	An antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.	Receptor tyrosine-protein kinase erbB-2target
Talazoparib	A poly-ADP ribose polymerase inhibitor used to treat HER2-, BRCA mutated locally advanced or metastatic breast cancer and HRR gene-mutated metastatic castration-resistant prostate cancer.	Poly [ADP-ribose] polymerase 1target Poly [ADP-ribose] polymerase 2target ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter
Trastuzumab	A monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.	Receptor tyrosine-protein kinase erbB-2target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01471847	A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab	Capecitabine Dactolisib Lapatinib Trastuzumab	treatment	1	completed
NCT00286247	Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer	No drug interventions	treatment	2	completed
NCT01240681	Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy	No drug interventions	diagnostic	Not Available	completed
NCT05963984	A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants	Fulvestrant Samuraciclib	treatment	2	active_not_recruiting
NCT06449222	Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy	No drug interventions	treatment	2	recruiting
NCT04360941	PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer	Avelumab Palbociclib	other	1	recruiting
NCT05415215	A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer	Hyaluronidase (human recombinant) Pertuzumab Trastuzumab Trastuzumab emtansine	treatment	3	active_not_recruiting
NCT06246968	A Study of Pembrolizumab and Cryoablation in People with Breast Cancer	Pembrolizumab	treatment	1	recruiting
NCT04699630	A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer	No drug interventions	treatment	2	recruiting
NCT06605521	To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients	No drug interventions	Not Available	Not Available	recruiting
NCT05002868	Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors	No drug interventions	treatment	1	completed
NCT05383196	Onvansertib + Paclitaxel in TNBC	Onvansertib Paclitaxel	treatment	1 / 2	recruiting
NCT05744375	Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab	Trastuzumab deruxtecan	treatment	2	recruiting
NCT06220214	Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer	Iohexol	diagnostic	0	recruiting
NCT04929964	COVID-19 Pandemic: Effect on Management of Patients With Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	Abemaciclib Anvatabart opadotin Cemiplimab Datopotamab deruxtecan Dostarlimab Doxorubicin Durvalumab Fianlimab Ganetespib Ganitumab Irinotecan Ladiratuzumab vedotin Lasofoxifene Letrozole Menthol Metformin Neratinib Olaparib Paclitaxel Patritumab Pembrolizumab Pertuzumab Pexidartinib SAR-439459 Talazoparib Trastuzumab Trastuzumab duocarmazine Trastuzumab emtansine Trebananib Trilaciclib Tucatinib Veliparib Vepdegestrant Zanidatamab	treatment	2	recruiting
NCT04669587	ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)	Palbociclib	treatment	1 / 2	unknown_status
NCT00237133	Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women	Letrozole	treatment	4	completed
NCT04042051	Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer	Copanlisib Trastuzumab emtansine	treatment	1	terminated
NCT03255577	Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer	No drug interventions	treatment	Not Available	recruiting
NCT01367288	Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers	Zoledronic acid	treatment	2	completed
NCT00756132	Using Bio Markers to Predict Disease Recurrence and Cognitive Function in High Risk Breast Ca	No drug interventions	Not Available	Not Available	completed
NCT06174259	Influence of Intermittent Fasting on Locally Advanced Breast Cancer Patients	No drug interventions	treatment	Not Available	recruiting
NCT01660542	An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer	Docetaxel	treatment	4	completed
NCT05582499	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	Adebrelimab Camrelizumab Carboplatin Cyclophosphamide Dalpiciclib Epirubicin Famitinib Fluzoparib Goserelin Letrozole Paclitaxel Pertuzumab Pyrotinib Rivoceranib Trastuzumab	treatment	2	recruiting
NCT05163106	Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole	Goserelin Letrozole Ribociclib	treatment	2	completed
NCT05809024	Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy	Letrozole	treatment	4	recruiting
NCT05749016	Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer	Carboplatin Inetetamab Paclitaxel Pertuzumab	treatment	2	recruiting
NCT04254263	Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer	Pyrotinib	treatment	3	recruiting
NCT03732339	CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial	No drug interventions	treatment	Not Available	completed
NCT00065325	The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer	Exemestane Fulvestrant	treatment	3	completed
NCT03685331	HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer	Fulvestrant Olaparib Palbociclib	treatment	1	active_not_recruiting
NCT00788489	A Prospective Study to Evaluate FDG-PET, Breast MRI, and Breast Ultrasonography in Monitoring Tumour Responses in Patients With Locally Advanced Breast Cancer (LABC) Undergoing Neoadjuvant Chemotherapy	No drug interventions	Not Available	Not Available	completed
NCT06499168	Predicting Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT05217381	Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status	No drug interventions	Not Available	Not Available	completed
NCT00395655	Hydralazine and Valproate Added to Chemotherapy for Breast Cancer	Hydralazine Valproic acid	treatment	2	terminated
NCT00623233	Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer	Bevacizumab Gemcitabine	treatment	2	completed
NCT04352777	Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer	Abemaciclib Fulvestrant	treatment	2	active_not_recruiting
NCT05963997	A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer	Elacestrant Samuraciclib	treatment	1 / 2	active_not_recruiting
NCT03329378	Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer	Carboplatin Cyclophosphamide Docetaxel Doxorubicin Paclitaxel Pegfilgrastim Pertuzumab Trastuzumab	treatment	2	terminated
NCT04088032	Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer	Abemaciclib Durvalumab	treatment	0	withdrawn
NCT05021900	Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer	Tenalisib	treatment	2	completed
NCT00764036	Study of Artesunate in Metastatic Breast Cancer	Artesunate	treatment	1	completed
NCT04899713	NEOZOL_Follow-up Study	No drug interventions	Not Available	Not Available	unknown_status
NCT01048918	Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT05233696	Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC	Paclitaxel Pembrolizumab	treatment	2	withdrawn
NCT03978663	Three Fraction Radiation to Induce Immuno-Oncologic Response	No drug interventions	treatment	Not Available	recruiting
NCT01837563	Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer	No drug interventions	Not Available	Not Available	terminated
NCT03924466	Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients	No drug interventions	diagnostic	2	recruiting
NCT06080620	The Choice of Treatment Methods and Efficacy of LABC	No drug interventions	treatment	Not Available	recruiting
NCT00455273	Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT02595762	A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer	No drug interventions	Not Available	Not Available	completed
NCT01785992	A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.	Irosustat	treatment	2	completed
NCT05957068	Breast Cancer Exercise Intervention Study	No drug interventions	treatment	Not Available	recruiting
NCT06064812	A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.	No drug interventions	treatment	1	recruiting
NCT02965950	The p53 Breast Cancer Trial	Cyclophosphamide	treatment	2	active_not_recruiting
NCT04318223	Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy	Palbociclib	treatment	2	unknown_status